Hematopoietic Stem Cells from Human Term Placenta

来自人类足月胎盘的造血干细胞

• 批准号: 8290455
• 负责人: Fernando Viteri
• 金额: $ 24.04万
• 依托单位: PLASALUS, LLC
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-07-01 至 2013-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8290455
• 关键词: Birth; Blinded; Blood Banks; Bone Marrow Transplantation; Cell Count; Cells; Child; Collaborations; Collection; Cryopreservation; Fred Hutchinson Cancer Research Center; Funding; Future; Guidelines; Harvest; Hematology; Hematopoietic; Hematopoietic stem cells; Human; Lead; Life; NCI Center for Cancer Research; National Institute of Diabetes and Digestive and Kidney Diseases; Patients; Pediatric Hospitals; Phase; Placenta; Preparation; Protocols documentation; Publications; Publishing; Reading; Research; Research Institute; Research Personnel; Resources; Scientist; Small Business Innovation Research Grant; Source; Staging; Stem cells; Techniques; Technology; Transplantation; Umbilical Cord Blood; Umbilical Cord Blood Transplantation; commercialization; experience; improved; new technology; novel; stem

DESCRIPTION (provided by applicant): Unfortunately only a fraction of patients in need of transplantation with hematopoietic stem cells can benefit from this life saving treatment. Successful transplantation requires sufficient numbers of immunologically-matched stem cells, a highly limited resource. Cord blood collected after the birth of the baby, is a validated source of hematopoietic stem and progenitor cells (HSPC). However, while the utilization of umbilical cord blood for transplantation is expanding, the cellular content of each unit severely limits its application. Moreover, more than half of the cord blood units collected are not stored in public cord blood banks, as the stem cell count does not warrant storage for future use. PlaSalus aims to define protocols that will overcome these limitations, by the use of human term placenta. Using novel technology we propose to develop the placenta as novel source for HSPC to augment and drastically improve the current available cell resources for bone marrow transplant. We aim to 1. Define collection and preparation protocols, compatible with various child birth settings, 2. Define cryopreservation protocols to allow long-term storage of placenta, compatible with current cord blood storage efforts, and 3. Define stem cell harvesting protocols, compatible with use in human transplant settings. PlaSalus will closely collaborate with experts from Children's Hospital Oakland Research Institute, and the Cancer Research Centers NIDDK funded Core Center of Excellence in Hematology in Seattle, to set the stage for the commercialization of this important resource.

描述（由申请人提供）：不幸的是，只有一小部分需要造血干细胞移植的患者可以从这种挽救生命的治疗中受益。成功的移植需要足够数量的免疫匹配干细胞，这是一种非常有限的资源。婴儿出生后收集的脐带血是造血干细胞和祖细胞 (HSPC) 的有效来源。然而，虽然脐带血用于移植的用途不断扩大，但每个单位的细胞含量严重限制了其应用。此外，一半以上收集的脐带血单位没有存储在公共脐带血库中，因为干细胞计数不能保证存储以供将来使用。 PlaSalus 旨在定义通过使用人类胎盘来克服这些限制的方案。我们建议利用新技术开发胎盘作为 HSPC 的新来源，以增强和大幅改善当前可用于骨髓移植的细胞资源。我们的目标是 1. 定义采集和准备方案，与各种分娩环境兼容；2. 定义低温保存方案，允许长期保存胎盘，与当前的脐带血储存工作兼容；3. 定义干细胞采集方案，兼容用于人体移植环境。 PlaSalus 将与奥克兰儿童医院研究所和 NIDDK 癌症研究中心资助的西雅图血液学核心卓越中心的专家密切合作，为这一重要资源的商业化奠定基础。